27es JNI 2026 PARIS
et la région Île-de-France Palais des Congrès
Journées Nationales d'infectiologie
du jeudi 18 juin au samedi 20 juin 2026
Journée Nationale de Formation des Paramédicaux en Infectiologie
Vendredi 19 juin 2026

Anticorps monoclonaux et vaccination antiVRS : l'expérience pédiatrique et les enseignements pour l'adulte

Naïm Ouldali
CHU Robert Debré, Paris

Déclaration d'intérêt de 2014 à 2025

- Intérêts financiers :
- Liens durables ou permanents : Financement de la recherche (Sanofi, Pfizer)
- Interventions ponctuelles : invitations en congrès (Sanofi, Pfizer, MSD)
- Intérêts indirects :

Depuis 2023

Depuis 2024

De nombreux succès : 1) Efficacité confirmée

Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis

Dewan Md Sumsuzzman, PhD [a] · Zhen Wang, PhD [a,b] · Joanne M Langley, MD [c] · Seyed M Moghadas, PhD [a]

Affiliations & Notes · Article Info · Linked Articles (1)

- Revue systématique et méta-analyses
- 32 cohortes inclues
- Effectiveness : odds ratio 0·17; 95% CI 0·12–0·23

Sumsuzzman et al, Lancet Child 2025

De nombreux succès : 1) Efficacité confirmée

Effectiveness of the maternal RSVpreF vaccine against severe disease in infants in Scotland, UK: a national, population-based case–control study and cohort analysis

Isobel McLachlan, Chris Robertson, Kirsty E Morrison, Ross McQueenie, Safraj Shahul Hameed, Cheryl Gibbons, Rachael Wood, Rachel Merrick, Louisa Pollock, Antonia Ho, Ting Shi, Thomas C Williams, Sir Aziz Sheikh, Jim McMenamin, Sam Ghebrehewet, Kimberly Marsh

	Cases	Controls	Adjusted vaccine effectiveness, % (95% CI)	p value
Unvaccinated	293	1788	0 (ref)	..
Vaccinated (>14 days before delivery)	43	1518	82·2% (75·1 to 87·3%)	<0·0001
<37 weeks' gestation	3	128	89·9% (55·3 to 97·7%)	0·0025
≥37 weeks' gestation	40	1390	81·5% (73·9 to 87·0%)	<0·0001
Suboptimal immunisation (≤14 days before delivery)	18	205	31·7% (−15·2 to 59·5%)*	0·20*



Figure 2: **Forest plot of maternal RSVpreF vaccine effectiveness against RSV-related LRTI hospital admission among infants aged 90 days or younger**
All estimates are compared with the unvaccinated group as the reference group. LRTI=lower respiratory tract infection. RSV=respiratory syncytial virus. RSVpreF=respiratory syncytial virus prefusion F protein. *Post-hoc analysis.

McLachan et al, LID 2025

De nombreux succès : 2) Acceptabilité inattendue !

De nombreux succès : 2) Acceptabilité inattendue !



RAPID COMMUNICATION

Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023

Federico Martinón-Torres[1,2,3,4], Susana Mirás-Carballal[5], Carmen Durán-Parrondo[5]

- Gallice : 93% d'immunisation parmi les nouveau-nés à partir du 25 septembre 2023
- France : acceptation autour de 90% !

Martinon-Torres et al, Eurosurveillance 2023

De nombreux succès : 3) Couverture élevée chez le petit nourrisson

De nombreux succès : 3) Couverture élevée chez le petit nourrisson

Part de la bronchiolite chez les enfants de moins de 1 an

Passages aux urgences



Source : réseau OSCOUR®

Hospitalisations après passage



Source : réseau OSCOUR®

https://www.santepubliquefrance.fr/sites/default/files/2026-04/bullnat_ira_20260415_VF_0.pdf

De nombreux succès : 3) Couverture élevée chez le petit nourrisson



https://www.santepubliquefrance.fr/sites/default/files/2026-04/bullnat_ira_20260415_VF_0.pdf

De nombreux succès : 4) Efficacité au-delà du VRS

Nirsevimab et infections invasives pneumococciques



Fafi et al, Lancet Inf Dis 2026, under press

Nirsevimab et infections invasives pneumococciques

	Immunized with nirsevimab *no. of IPD cases in each group/total no. (no. of IPD cases in each group/100,000)*	Non-immunized with nirsevimab	OR [95%CI]
Primary analysis*	17/119,435 (14.2/100,000)	95/408,530 (23.3/100,000)	0.64 [0.48;0.85]

Fafi et al, Lancet Inf Dis 2026, under press

Nirsevimab et infections invasives pneumococciques

	Immunized with nirsevimab *no. of IPD cases in each group/total no. (no. of IPD cases in each group/100,000)*	Non-immunized with nirsevimab	OR [95%CI]
Primary analysis*	17/119,435 (14.2/100,000)	95/408,530 (23.3/100,000)	0.64 [0.48;0.85]
Sensitivity analyses			
Matching immunized / non-immunized children (1:2) †	12/76,846 (15.6/100,000)	42/153,692 (27.3/100,000)	0.64 [0.43;0.95]
Double-robust adjustment ‡	17/119,435 (14.2/100,000)	95/408,530 (23.3/100,000)	0.64 [0.48;0.85]
Random intercept for region §	17/119,435 (14.2/100,000)	95/408,530 (25.0/100,000)	0.64 [0.48;0.85]
Removing IPD cases defined by code B953 + meningitis, bacteremia, pneumonia, osteoarticular infection or mastoiditis ¶	17/119,435 (14.2/100,000)	81/408,530 (19.8/100,000)	0.64 [0.47;0.86]
Average effect in the treated population ††	17/119,435 (14.2/100,000)	95/408,530 (23.3/100,000)	0.64 [0.42;0.96]
Propensity score matching ‡‡	17/119,434 (14.2/100,000)	53/211,811 (25.0/100,000)	0.57 [0.33;0.98]
Overlap-weighting §§	17/119,435 (14.2/100,000)	95/408,530 (23.3/100,000)	0.65 [0.43;0.96]
Trimming ¶¶	16/113,463 (14.1/100,000)	91/388,103 (23.4/100,000)	0.57 [0.42;0.78]
Attribution of inclusion dates for non-immunized children regardless of birth month †††	17/119,435 (14.2/100,000)	91/408,522 (22.3/100,000)	0.69 [0.42;0.78]
Previous severe infections included in the PS ‡‡‡	17/119,435 (14.2/100,000)	95/408,530 (23.3/100,000)	0.62 [0.48;0.84]
Other acquired immunodeficiencies included in the PS §§§	17/119,435 (14.2/100,000)	95/408,530 (23.3/100,000)	0.64 [0.48;0.85]
Nirsevimab receipt considered with a seven-day delay ¶¶¶	17/119,435 (14.2/100,000)	91/408,526 (22.3/100,000)	0.67 [0.51;0.90]
Age categorized as < 3 months or ≥ 3 months	17/119,435 (14.2/100,000)	95/408,530 (23.3/100,000)	0.62 [0.46;0.82]

Fafi et al, Lancet Inf Dis 2026, under press

Nirsevimab et otites moyennes aiguës

Nirsevimab et otites moyennes aiguës



Fafi et al, CID 2026

Des challenges persistants : 1) Couverture chez l’enfant né avant la campagne

- Actuellement : 50%

Des challenges persistants : 1) Couverture chez l'enfant né avant la campagne

Part de la bronchiolite chez les enfants de moins de 1 an

Passages aux urgences



Source : réseau OSCOUR®

Hospitalisations après passage



Source : réseau OSCOUR®

https://www.santepubliquefrance.fr/sites/default/files/2026-04/bullnat_ira_20260415_VF_0.pdf

Des challenges persistants : 2) Couverture et inégalités sociales

Figure. Association Between Socioeconomic and Health Care Accessibility and Outpatient Nirsevimab Immunization

Indicators	Infants, No. (%) (N = 328 131)		OR (95% CI)	
	Immunized (n = 42 082)	Not immunized (n = 286 049)	Crude	Adjusted
General characteristics				
Sex				
Female	19 937 (47.4)	140 576 (49.1)	1 [Reference]	1 [Reference]
Male	22 145 (52.6)	145 473 (50.9)	1.07 (1.05-1.10)	1.07 (1.05-1.10)
Gestational age, wk				
Full term (≥37)	39 526 (93.9)	271 991 (95.1)	1 [Reference]	1 [Reference]
Moderate preterm (32-37)	2235 (5.3)	12 691 (4.4)	1.21 (1.16-1.27)	1.34 (1.27-1.41)
Very preterm (<32)	321 (0.8)	1367 (0.5)	1.62 (1.43-1.83)	2.07 (1.82-2.37)
Birth weight (P)				
Small (<10)	3476 (8.3)	23 226 (8.1)	1.02 (0.99-1.06)	0.98 (0.94-1.03)
Appropriate weight (10-90)	35 007 (83.2)	239 566 (83.7)	1 [Reference]	1 [Reference]
Large (>90)	3599 (8.6)	23 257 (8.1)	1.06 (1.02-1.10)	1.04 (1.00-1.08)
Birth period				
February 6 to March 31, 2023	8173 (19.4)	74 409 (26.0)	1 [Reference]	1 [Reference]
April 1 to May 31, 2023	12 154 (28.9)	79 072 (27.6)	1.40 (1.36-1.44)	1.40 (1.35-1.44)
June 1 to July 31, 2023	14 747 (35.0)	79 880 (27.9)	1.68 (1.63-1.73)	1.69 (1.64-1.74)
August 1-31, 2023	5440 (12.9)	40 301 (14.1)	1.23 (1.19-1.27)	1.22 (1.18-1.27)
September 1-15, 2023	1568 (3.7)	12 387 (4.3)	1.15 (1.09-1.22)	1.14 (1.08-1.21)
Social security affiliation type				
General health scheme	40 848 (97.1)	277 523 (97.0)	1 [Reference]	1 [Reference]
Agricultural scheme	725 (1.7)	5818 (2.0)	0.85 (0.78-0.92)	0.86 (0.79-0.93)
Other[a]	509 (1.2)	2708 (0.9)	1.28 (1.16-1.40)	1.15 (1.04-1.29)
Socioeconomic indicators				
French Deprivation Index, quintile				
5 (More deprived)	5342 (12.7)	60 102 (21.0)	0.37 (0.36-0.38)	0.41 (0.39-0.42)
4	6350 (15.1)	56 476 (19.7)	0.47 (0.45-0.48)	0.50 (0.48-0.52)
3	8014 (19.0)	56 587 (19.8)	0.59 (0.57-0.61)	0.59 (0.57-0.61)
2	9437 (22.4)	58 028 (20.3)	0.68 (0.66-0.70)	0.67 (0.64-0.69)
1 (Less deprived)	12 562 (29.9)	52 408 (18.3)	1 [Reference]	1 [Reference]
Missing	377 (0.9)	2448 (0.9)	0.64 (0.58-0.72)	0.62 (0.53-0.74)
Type of birth hospital				
Public	27525 (65.4)	211 038 (73.8)	0.67 (0.66-0.69)	0.81 (0.79-0.83)
Private	14 557 (34.6)	75 011 (26.2)	1 [Reference]	1 [Reference]
Regional distribution				
Bourgogne-Franche-Comté	956 (2.3)	11 167 (3.9)	0.58 (0.54-0.63)	0.76 (0.71-0.82)
Occitanie	2997 (7.1)	25 112 (8.8)	0.81 (0.78-0.85)	0.85 (0.81-0.89)
Provence-Alpes-Côte d'Azur	3355 (8.0)	23 298 (8.1)	0.98 (0.94-1.02)	0.97 (0.93-1.02)
Ile-de-France	9629 (22.9)	65 593 (22.9)	1 [Reference]	1 [Reference]
Auvergne-Rhône-Alpes	4886 (11.6)	34 277 (12.0)	0.97 (0.94-1.01)	1.03 (0.99-1.07)
Bretagne	2144 (5.1)	13 434 (4.7)	1.09 (1.03-1.14)	1.09 (1.03-1.15)
Pays de la Loire	2570 (6.1)	16 999 (5.9)	1.03 (0.98-1.08)	1.19 (1.13-1.25)
Nouvelle-Aquitaine	3438 (8.2)	21 178 (7.4)	1.11 (1.06-1.15)	1.21 (1.16-1.27)
Grand Est	3312 (7.9)	21 605 (7.6)	1.04 (1.00-1.09)	1.26 (1.20-1.32)
Centre-Val de Loire	1671 (4.0)	10 795 (3.8)	1.05 (1.00-1.11)	1.45 (1.37-1.54)
Hauts-de-France	4601 (10.9)	27 682 (9.7)	1.13 (1.09-1.18)	1.49 (1.43-1.56)
Corse	176 (0.4)	855 (0.3)	1.40 (1.19-1.65)	1.53 (1.30-1.81)
Normandie	2347 (5.6)	14 054 (4.9)	1.14 (1.08-1.19)	1.57 (1.49-1.65)



JAMA Network Open

Research Letter | Pediatrics

Sociodemographic Characteristics of Infants Receiving Nirsevimab

Salomé Boutin, MPH; Marion Bertrand, Msc; Jérémie F. Cohen, MD, PhD; Mahmoud Zureik, MD, PhD; Martin Chalumeau, MD, PhD; Marie-Joëlle Jabagi, PharmD, PhD

JAMA Network Open.

Research Letter | Infectious Diseases

Social and Regional Inequalities in Maternal Respiratory Syncytial Virus Vaccination in France

Amélie Gabet, PhD; Marion Bertrand, MSc; Marie-Joëlle Jabagi, PhD; Valérie Olié, PhD; Mahmoud Zureik, MD, PhD

Table 1. Association of Participant Characteristics With Bivalent Recombinant Respiratory Syncytial Virus Vaccination in France

Characteristic	Women, No. (%) (N = 264 471)		Vaccination rate, No./total No. (%)	Vaccination, OR (95% CI)	
	Vaccinated (n = 72 026)	Not vaccinated (n = 192 445)		Crude	Adjusted[a]
Age group, y					
13-17	191 (0.3)	1316 (0.7)	191/1 507 (12.7)	0.49 (0.42-0.57)	0.77 (0.65-0.90)
18-24	7909 (11.0)	29 999 (15.6)	7909/37 908 (20.9)	0.77 (0.75-0.80)	0.88 (0.85-0.91)
25-29	19 821 (27.5)	56 161 (29.2)	19 821/75 982 (26.1)	1 [Reference]	1 [Reference]
30-39	40 956 (56.9)	96 364 (50.1)	40 956/137 320 (29.8)	1.20 (1.18-1.23)	1.16 (1.13-1.18)
40-50	3149 (4.4)	8605 (4.5)	3149/11 754 (26.8)	1.06 (1.01-1.11)	1.08 (1.03-1.13)
Socioeconomic indicators					
Complementary solidarity health insurance	9108 (12.6)	48 677 (25.3)	9108/57 785 (15.8)	0.46 (0.45-0.47)	0.51 (0.50-0.53)
French Deprivation Index, quintile					
First (less deprived)	18 096 (25.1)	35 770 (18.6)	18 096/53 866 (33.6)	1.79 (1.75-1.85)	1.82 (1.76-1.88)
Second	15 808 (22.0)	36 213 (18.8)	15 808/52 021 (30.4)	1.55 (1.51-1.59)	1.43 (1.39-1.47)
Third	13 703 (19.0)	35 716 (18.6)	13 703/49 419 (27.7)	1.36 (1.32-1.40)	1.29 (1.25-1.33)
Fourth	12 425 (17.3)	35 093 (18.2)	12 425/47 518 (26.1)	1.26 (1.22-1.29)	1.15 (1.12-1.19)
Fifth (more deprived)	10 691 (14.8)	37 935 (19.7)	10 691/48 626 (22.0)	1 [Reference]	1 [Reference]
Oversea territories	771 (1.1)	10 437 (5.4)	771/11 208 (6.9)	1.14 (0.93-1.39)	1.31 (1.07-1.60)
Missing	532 (0.7)	1281 (0.7)	532/1813 (29.3)	NA	NA
Health care accessibility level[b]					
1 (Lower accessibility)	21 332 (29.6)	65 848 (34.2)	21 332/87 180 (24.5)	1 [Reference]	1 [Reference]
2	23 674 (32.9)	62 702 (32.6)	23 674/83 376 (27.4)	1.15 (1.13-1.18)	1.16 (1.13-1.18)
3 (Higher accessibility)	25 784 (35.8)	59 728 (31.0)	25 784/86 512 (30.2)	1.37 (1.34-1.40)	1.26 (1.23-1.29)
Missing	1236 (1.7)	4167 (2.2)	1236/5403 (22.9)	NA	NA
Region of residence					
Auvergne-Rhône-Alpes	9358 (13.0)	22 135 (11.5)	9358/31 493 (29.7)	0.56 (0.54-0.59)	0.54 (0.52-0.57)
Bourgogne-Franche-Comté	1967 (2.7)	7069 (3.7)	1967/9036 (21.8)	0.37 (0.35-0.39)	0.41 (0.38-0.44)
Bretagne	4921 (6.8)	6563 (3.4)	4921/11 484 (42.9)	1 [Reference]	1 [Reference]
Centre-Val de Loire	2597 (3.6)	6841 (3.6)	2597/9538 (27.5)	0.51 (0.48-0.54)	0.56 (0.53-0.60)
Corse	134 (0.2)	682 (0.4)	134/816 (16.4)	0.26 (0.22-0.32)	0.24 (0.20-0.29)
Grand Est	4545 (6.3)	14 325 (7.5)	4545/18 870 (24.1)	0.42 (0.40-0.44)	0.47 (0.44-0.49)
Hauts-de-France	7335 (10.2)	17 199 (9.0)	7335/24 534 (29.9)	0.57 (0.54-0.60)	0.70 (0.67-0.73)
Ile-de-France	14 309 (19.9)	45 939 (23.9)	14 309/60 248 (23.8)	0.42 (0.40-0.43)	0.36 (0.35-0.38)
Normandie	3636 (5.1)	8571 (4.5)	3636/12 207 (29.8)	0.57 (0.54-0.60)	0.65 (0.62-0.69)
Nouvelle-Aquitaine	6902 (9.6)	12 565 (6.5)	6902/19 467 (35.5)	0.73 (0.70-0.77)	0.75 (0.72-0.79)
Occitanie	6025 (8.4)	14 805 (7.7)	6025/20 830 (28.9)	0.54 (0.52-0.57)	0.58 (0.55-0.60)
Pays de la Loire	5129 (7.1)	9317 (4.9)	5129/14 446 (35.5)	0.73 (0.70-0.77)	0.75 (0.71-0.79)
Provence-Alpes-Côte d'Azur	4487 (6.2)	15 970 (8.3)	4487/20 457 (21.9)	0.37 (0.36-0.39)	0.38 (0.36-0.40)

(continued)

Des questions persistantes

- Quelle efficacité d'une année sur l'autre, selon les clades de VRS ?
- Quel risque d'émergence de résistance ?
- Quel impact à moyen terme ?

Au total

- Une expérience unique, redessinant le profil des épidémies hivernales
- Un impact bien au-delà de la bronchiolite
- Un modèle pouvant guider les futures stratégies vaccinales
- Des challenges persistants, des questions majeures à adresser

Remerciements

Tous les investigateurs impliqués dans ces observatoires